ALFA Finder| Management target | Revenue 14.0% FY27 |
|---|
| Revenue growth | 13% consolidated, 14% domestic formulations growth; insulin franchise scaling. |
|---|---|
| Margins | Gross margins contracted 300bps due to higher biologics/insulin product mix. |
| Demand visibility | Strong demand in chronic therapies; cardiac segment expected to normalize soon. |
| Management confidence | Confident but cautious regarding near-term margin trade-offs for biologic growth. |
Growth
Domestic formulations grew 14% with 7/10 therapies in double digits; insulin and Semaglutide show strong early momentum.
Outlook
Management guides 14% revenue growth for FY27, aiming for a 300bps premium over 11% market growth.
Risks
Gross margins dipped 300bps; Biocom's insulin integration and manufacturing shifts at Bhopal may cause near-term volatility.
Earnings Call Transcript filed with NSE, NSE: ERIS. Summary written with AI assistance from the document.
Eris Lifesciences Ltd: key numbers
- Share price
- ₹1,275.10
- Market cap
- ₹17,691 Cr
- Revenue (annual)
- ₹3,129 Cr
- Net profit (annual)
- ₹619.5 Cr
- P/E (TTM)
- 25.0×Sector 43.8×
- Promoter holding
- 54.74%+0.60% QoQ
- FII holding
- 5.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Eris Lifesciences Ltd
All →Eris Lifesciences Annual General Meeting
Eris Lifesciences has issued a postal ballot notice seeking members' approval to appoint Mr. Akhil Awasthi as Independent Director for five years from 26 September 2026. E-voting runs 6 November to 5 December 2026.
- Execution
- 26 September 2026 to 25 September 2031
Eris Lifesciences Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹892 Cr (+12.6%), PAT ₹187 Cr (+39.2%), EBITDA margin 34.7%. H1 PAT ₹330 Cr (+27.3%). Zorvia out-licensing supports DBF gross margin.
Eris Lifesciences Q2 FY27 Results: Net Profit ₹187.1 Cr, Up 39.1% YoY
Eris Lifesciences Ltd reported revenue from operations of ₹892.4 Cr (+12.6% YoY) and net profit of ₹187.1 Cr (+39.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹187.1 Cr · +39.1% YoY
Eris Lifesciences Board Meeting Date
Eris Lifesciences has scheduled a board meeting for October 26, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter ending September.
Eris Lifesciences Other Announcement
Eris Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Eris Lifesciences Debt & Borrowing: ₹1,250 Cr
Eris Lifesciences Limited submitted its half-yearly reporting of debt securities for the period ended September 30, 2026. Two tranches of NCDs totaling ₹1,250 Crore remain outstanding.
- Value
- ₹1,250 Cr